- Alternative Splicing
- Avian Leukosis Virus
- Avian Sarcoma Viruses
- Cleavage Stimulation Factor
- Heterogeneous-Nuclear Ribonucleoprotein Group A-B
- Heterogeneous-Nuclear Ribonucleoprotein Group F-H
- mRNA Cleavage and Polyadenylation Factors
- Ribonucleoproteins, Small Nuclear
- RNA 3' Polyadenylation Signals
- RNA Precursors
- Chair, Course Evaluation Committee, Graduate School
- Course Director, IAHI, M1 Medical School
- Faculty Advisor, Research and Education Program, AHW
My laboratory uses molecular, genetic, biochemical, and cell biological approaches to study post-transcriptional mechanisms of gene regulation, including RNA splicing and polyadenylation control. One area of focus uses the simple retrovirus, Rous sarcoma virus (RSV), to understand the role of RNA processing in the virus life cycle. We are also exploiting antisense oligonucleotide technologies to alter RNA splicing as an approach to develop a breast cancer therapeutic.
RNA Splicing Control in RSV
It is now appreciated that many RNA processing events, including splicing and polyadenylation, are coupled. Thus, there is great interest in understanding the mechanisms of alternative splicing/polyadenylation and how coupling occurs. Retroviruses such as RSV exploit the host cell RNA processing machinery in interesting ways and serve as model systems to study RNA processing. RSV generates subgenomic (spliced) mRNAs, but the majority of the primary transcripts remains unspliced and serves as mRNA for structural proteins and as genome for progeny virions. In contrast, host RNAs are usually spliced to completion, so the virus has evolved mechanism to repress splicing of viral RNA. The accumulation of RSV unspliced RNA is in part explained by the action of a novel cis-acting RNA element, the negative regulator of splicing, or NRS, which acts as a pseudo 5' ss that serves to repress splicing at the RSV alternative 3' splice sites. The viral element binds several proteins of the "SR protein" family, which serve to recruit U1 snRNP to a downstream pseudo-5'ss. NRS can then interact with the viral splice sites to form an aberrant, non-productive splicing complex that sequesters the viral 3'ss and prevents their association with the authentic 5'ss; splicing inhibition results. The NRS also binds hnRNP H, which recruits U11 snRNP of the minor splicing pathway to a site that overlaps the U1 site; U11 thus fine-tunes NRS splicing control.
Figure 1. Model for NRS function. SR proteins bind to the NRS (red) purine-rich region and facilitate binding of U1 snRNP to the 3' end of the NRS. U1 snRNP bound to the NRS interacts with the viral 3' ss to assemble a non-productive complex that inhibits splicing. U11 binding would prevent U1 binding and assembly of the NRS complex, and allow the potential for viral RNA splicing.
Polyadenylation Control in RSV
Because the processes of RNA splicing and polyadenylation are coupled, the means by which unspliced viral RNA is efficiently polyadenylated is also of interest. Interestingly, the NRS serves a second purpose in promoting polyadenylation. The viral polyadenylation site is inherently weak and we made the novel finding that SR proteins, in the context of the inhibitory NRS complex, stimulate use of the weak RSV poly(A) site in cooperation with SR proteins bound to the env splicing enhancer; the two sites require juxtaposition via the NRS complex. Current work suggests that a threshold of SR proteins is required for coupling to the distant viral polyA site.
Antisense oligonucleotides (ASO) targeting SmgGDS and Breast Cancer
Recent advances from genomic, bioinformatic, and high-throughput approaches to studying RNA splicing demonstrated that alternative splicing and alternative polyadenylation are very widespread in humans, and deregulation of alternative splicing and polyadenylation is common in human disease, including cancer. We are collaborating with Dr. Carol Williams (Pharmacology and Toxicology) to modify splicing of SmgGDS as a potential therapy for breast cancer. The Williams lab has worked extensively on two splice isoforms of SmgGDS (SmgGDS-607 and -558) that regulate prenylation and membrane trafficking of small GTPases involved in tumorigenesis. Significantly, their work has shown in cultured cells and a mouse xenograft model of breast cancer that reduction of the -558 isoform slows tumor growth, and has therapeutic potential. We demonstrated that ASO reduction of -558 splicing and protein production in cultured breast cancer cells reduces cancer cell proliferation, and are pursuing mouse models to validate ASOs as a promising breast cancer therapeutic.
(Brandt AC, McNally L, Lorimer EL, Unger B, Koehn OJ, Suazo KF, Rein L, Szabo A, Tsaih SW, Distefano MD, Flister MJ, Rigo F, McNally MT, Williams CL.) Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3627-3636 PMID: 32019878 PMCID: PMC7035473 SCOPUS ID: 2-s2.0-85079538992 02/06/2020
(Hudson SW, McNally LM, McNally MT.) Virology. 2016 11;498:181-191 PMID: 27596537 PMCID: PMC5045808 SCOPUS ID: 2-s2.0-84985990676 09/07/2016
(Runge CL, Erbe CB, McNally MT, Van Dusen C, Friedland DR, Kwitek AE, Kerschner JE.) Audiol Neurootol. 2013;18(6):374-82 PMID: 24135434 PMCID: PMC3877672 SCOPUS ID: 2-s2.0-84885522606 10/19/2013
(Hudson SW, McNally MT.) J Virol. 2011 Nov;85(21):11351-60 PMID: 21849435 PMCID: PMC3194969 SCOPUS ID: 2-s2.0-80055120941 08/19/2011
(Van Dusen CM, Yee L, McNally LM, McNally MT.) Mol Cell Biol. 2010 May;30(10):2552-62 PMID: 20308327 PMCID: PMC2863714 SCOPUS ID: 2-s2.0-77951990307 03/24/2010
(Hassemer EL, Le Gall SM, Liegel R, McNally M, Chang B, Zeiss CJ, Dubielzig RD, Horiuchi K, Kimura T, Okada Y, Blobel CP, Sidjanin DJ.) Genetics. 2010 May;185(1):245-55 PMID: 20194968 PMCID: PMC2870960 SCOPUS ID: 2-s2.0-77956635945 03/03/2010
(Mitton E, Gohr CM, McNally MT, Rosenthal AK.) Biochem Biophys Res Commun. 2009 Oct 23;388(3):533-8 PMID: 19679100 PMCID: PMC2754773 SCOPUS ID: 2-s2.0-69549117350 08/15/2009
(Maciolek NL, McNally MT.) Virology. 2008 May 10;374(2):468-76 PMID: 18272196 PMCID: PMC2413101 SCOPUS ID: 2-s2.0-42649140232 02/15/2008
(McNally MT.) Front Biosci. 2008 May 01;13:3869-83 PMID: 18508481 PMCID: PMC2575692 SCOPUS ID: 2-s2.0-42649114510 05/30/2008
(Maciolek NL, McNally MT.) J Virol. 2007 Oct;81(20):11208-17 PMID: 17670832 PMCID: PMC2045511 SCOPUS ID: 2-s2.0-35148860145 08/03/2007
(Sun HY, McNally MT, Jackson VE, Grossberg SE.) J Virol Methods. 2006 Nov;137(2):304-8 PMID: 16920200 PMCID: PMC2575689 SCOPUS ID: 2-s2.0-33748714112 08/22/2006
(Maciolek NL, Alward WL, Murray JC, Semina EV, McNally MT.) BMC Med Genet. 2006 Jul 11;7:59 PMID: 16834779 PMCID: PMC1553432 SCOPUS ID: 2-s2.0-33748048489 07/13/2006